Financials Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.19 USD | +0.25% |
|
+8.30% | +2.92% |
Projected Income Statement: Edwards Lifesciences Corporation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 4,348 | 4,386 | 5,232 | 5,382 | 6,005 | 5,440 | 5,841 | 6,421 |
Change | - | 0.88% | 19.29% | 2.86% | 11.56% | -9.41% | 7.37% | 9.93% |
EBITDA 1 | 1,406 | 1,429 | 1,729 | 1,936 | 1,879 | 1,796 | 1,765 | 1,982 |
Change | - | 1.67% | 21% | 11.96% | -2.96% | -100% | -1.75% | 12.3% |
EBIT 1 | 1,316 | 1,322 | 1,594 | 1,796 | 1,734 | 1,514 | 1,592 | 1,804 |
Change | - | 0.43% | 20.61% | 12.67% | -3.49% | -12.65% | 5.12% | 13.3% |
Interest Paid | 11.5 | 7.6 | -1 | 16.3 | 49.6 | 100.5 | -7 | -3 |
Earnings before Tax (EBT) 1 | 1,166 | 916.7 | 1,702 | 1,767 | 1,598 | 1,548 | 1,684 | 1,914 |
Change | - | -21.41% | 85.67% | 3.84% | -9.58% | -3.13% | 8.79% | 13.62% |
Net income 1 | 1,047 | 823.4 | 1,503 | 1,522 | 1,402 | 4,175 | 1,416 | 1,588 |
Change | - | -21.35% | 82.55% | 1.25% | -7.85% | 197.68% | -66.09% | 12.2% |
Announcement Date | 1/30/20 | 1/27/21 | 1/26/22 | 1/31/23 | 2/6/24 | 2/11/25 | - | - |
Forecast Balance Sheet: Edwards Lifesciences Corporation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | -585 | -588 | -267 | -173 | -1,048 | -3,692 | -3,658 | -4,617 |
Change | - | -200.51% | -145.41% | -164.79% | -705.78% | -452.46% | -199.08% | -226.22% |
Announcement Date | 1/30/20 | 1/27/21 | 1/26/22 | 1/31/23 | 2/6/24 | 2/11/25 | - | - |
Cash Flow Forecast: Edwards Lifesciences Corporation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 254.4 | 407 | 325.8 | 244.6 | 253 | 288.8 | 259.2 | 287.7 |
Change | - | 59.98% | -19.95% | -24.92% | 3.43% | 14.15% | -10.24% | 11% |
Free Cash Flow (FCF) 1 | 925 | 647.3 | 1,406 | 973.6 | 943 | 1,268 | 1,407 | 1,552 |
Change | - | -30.02% | 117.26% | -30.77% | -3.14% | 34.45% | 10.97% | 10.28% |
Announcement Date | 1/30/20 | 1/27/21 | 1/26/22 | 1/31/23 | 2/6/24 | - | - | - |
Forecast Financial Ratios: Edwards Lifesciences Corporation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
EBITDA Margin (%) | 32.33% | 32.58% | 33.05% | 35.97% | 31.29% | 30.43% | 30.21% | 30.87% |
EBIT Margin (%) | 30.28% | 30.14% | 30.47% | 33.38% | 28.87% | 27.84% | 27.26% | 28.09% |
EBT Margin (%) | 26.83% | 20.9% | 32.53% | 32.84% | 26.61% | 28.46% | 28.84% | 29.81% |
Net margin (%) | 24.08% | 18.77% | 28.73% | 28.28% | 23.35% | 76.75% | 24.24% | 24.74% |
FCF margin (%) | 21.27% | 14.76% | 26.88% | 18.09% | 15.7% | 21.48% | 24.09% | 24.16% |
FCF / Net Income (%) | 88.36% | 78.61% | 93.56% | 63.97% | 67.24% | 91.72% | 99.39% | 97.69% |
Profitability | ||||||||
ROA | 20.03% | 17.11% | 17.84% | 18.46% | 15.89% | 12.76% | 11.6% | 12.12% |
ROE | 32.46% | 26.92% | 26.97% | 26.64% | 22.52% | 19.23% | 15.71% | 15.25% |
Financial Health | ||||||||
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
CAPEX / Current Assets (%) | 5.85% | 9.28% | 6.23% | 4.54% | 4.21% | 4.89% | 4.44% | 4.48% |
CAPEX / EBITDA (%) | 18.1% | 28.48% | 18.84% | 12.63% | 13.47% | 16.08% | 14.69% | 14.52% |
CAPEX / FCF (%) | 27.5% | 62.88% | 23.17% | 25.12% | 26.83% | 22.78% | 18.43% | 18.55% |
Items per share | ||||||||
Cash flow per share 1 | 1.853 | 1.668 | 2.74 | 1.952 | 1.47 | 0.1374 | 2.833 | 3.172 |
Change | - | -9.94% | 64.22% | -28.76% | -24.69% | -90.65% | 1,961.41% | 11.97% |
Dividend per Share 1 | - | - | - | - | - | - | - | - |
Change | - | - | - | - | - | - | - | - |
Book Value Per Share 1 | 6.504 | 7.188 | 9.351 | 9.546 | 10.91 | 14.99 | 17.06 | 17.39 |
Change | - | 10.51% | 30.1% | 2.09% | 14.31% | 37.34% | 13.85% | 1.9% |
EPS 1 | 1.643 | 1.3 | 2.38 | 2.44 | 2.3 | 6.97 | 2.384 | 2.7 |
Change | - | -20.89% | 83.08% | 2.52% | -5.74% | 203.04% | 3.31% | 13.25% |
Nbr of stocks (in thousands) | 625,710 | 623,248 | 624,334 | 618,260 | 606,500 | 589,800 | 589,800 | 589,800 |
Announcement Date | 1/30/20 | 1/27/21 | 1/26/22 | 1/31/23 | 2/6/24 | 2/11/25 | - | - |
2024 | 2025 * | |
---|---|---|
P/E ratio | 10.6x | 32x |
PBR | 5.08x | 4.47x |
EV / Sales | 8.03x | 7.07x |
Yield | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
- Financials Edwards Lifesciences Corporation